The 1^st edition of the 3D PharmaPrint Healthcare Symposium will take place on Tuesday March 18^th in Rotterdam, The Netherlands.

The PharmaPrint Healthcare Symposium, a collaborative initiative by TNO and Erasmus Medical Center, seeks to bridge the gap between pharmaceuticals and healthcare through the lens of 3D printing. By uniting thought leaders and pioneers in the field, our objective is to shape the future of healthcare, fostering precision medicine, and pushing the boundaries of what’s achievable in the realm of healthcare. Our goal is to create a dynamic space for experts, researchers, and industry leaders to exchange insights, accelerate innovation, and pave the way for a future where personalized medicine meets cutting-edge technology.

 

Program

The preliminary program is available here. Sneak preview of the speakers and panel members can be found below.

Registration

For registration click on ‘Online registratie’ (right side of the page)
You can register for the symposium until Monday March 10^th, 2025.

 

Venue

Buitenplaats Rozenlust
Parklaan 11
3016 BA Rotterdam
Website Rozenlust: https://rozenlust.nl/ 

 

 

Poster

If you are interested in presenting a poster, please submit an abstract (up to 200 words) to 3DPPHSymposium@erasmusmc.nl by February 10^th.

 

Accreditation

Accreditation requested by NVZA en KNMP

 

Accessibility venue:

Public Transport
Tram line 7 (from Rotterdam Central Station) stops 400 meters away. Metro station Leuvehaven is a 5-minute walk. By bike, it’s about 10 minutes from Rotterdam Central Station.
Ferry
You can also arrive by ferry. Disembark at Rotterdam Erasmus Bridge.
Car & parking
Accessible by car via the A16 (exit 25 Rotterdam Centrum) or the A13 (exit Stadhoudersweg).
You can park on our premises, but there are limited spots available. Parking at Erasmus MC is also available, this will be within a short 10 minute walk.

 

City, hotels & travel

Visit this website  for more information about hotels, drinks & dining and travel in Rotterdam.

Hotels nearby the venue  Buitenplaats Rozenlust:
DoubleTree by Hilton Rotterdam Centre – website
Sonder Rose – website
Bilderberg Parkhotel Rotterdam – website

 

Organisation

 

 

 

 

 

 

 

 

 

 

 

 

Liesbeth Ruijgrok is a hospital pharmacist and researcher that is highly motivated to improve the availability of suitable medicines for neglected patient groups. She has been working in Erasmus MC since 2018. She is Principal Investigator in the Research Pillar “Drug Innovation and Drug Development” of the Hospital Pharmacy. She is an enthusiastic collaborator in several scientific projects that concern in-academia development of drugs, varying from small molecules to cell therapy products (ATMP) and cancer vaccines. Since 2019 she has been working in the field of 3D-printing, in close collaboration with TNO. She sees that the 3D-printing technology can substantially enlarge personalized treatment options since it allows for flexible and tuneable drug compounding. She is affiliated to a growing Dutch and European consortium in this field and currently supervises 4 PhD students on the topic of 3D pharmaprinting. Her ultimate goal: to bring this exciting new technology as soon as possible to the benefit of patients!

Julian Quodbach is a pharmacist by training with a PhD in pharmaceutics from Heinrich Heine University Düsseldorf in Germany. Since 2015 he is researching 3D printing as manufacturing tool for pharmaceutical products. After a postdoc at the Drug Delivery Group at Uppsala University, Sweden in 2019, Julian Quodbach returned to Düsseldorf to continue his work on 3D printing. In January 2022, Julian joined the Utrecht Institute for Pharmaceutical Sciences at Utrecht University, The Netherlands as Assistant Professor. There, he connects his academic work on 3D printing of medicines with clinical translation and application.

Dr. Jayeeta Sengupta is a biologist specializing in drug development, nanomedicine, and bridging research with business innovation. She has held both academic and industry positions globally in different organizations. She has contributed to impactful research and authored multiple publications. Her current role is Program Manager Science & Technology, Unit High Tech Industry at TNO.

Amanda Holst is a PhD candidate at Erasmus MC’s Hospital Pharmacy in Rotterdam, Netherlands, specializing in the 3D printing of pediatric medications. She holds a degree in biopharmaceutical sciences from Leiden University, where she combined research and business specializations during her master’s. Her research aims to harness 3D printing technology to create personalized medicines tailored to the unique needs of pediatric patients. This innovative approach allows for customization in dosage, shape, flavor, and drug combinations, improving both treatment efficacy and patient compliance. The project encompasses the development of optimal formulations, followed by clinical trials to assess the effectiveness and safety of the 3D-printed medications.

Eveline van Kampen is a PhD candidate and research coordinator at Erasmus MC’s Hospital Pharmacy in Rotterdam, Netherlands. With a background in chemical engineering and bio-pharmaceutical sciences, she brings a unique perspective to her research. Her work focuses on innovative pharmaceutical technologies, particularly the application of 3D printing to develop age- and dose-appropriate medications for pediatric patients. Before joining Erasmus MC, she conducted research exploring hot-melt extrusion for pharmaceutical formulations. She also served as a clinical trial manager at Hematologie Oncologie Volwassenen Onderzoek Nederland in Rotterdam. Her academic journey includes a Master’s in Bio-Pharmaceutical Sciences from Leiden University and a Bachelor’s in Chemical Engineering from the University of Twente. Throughout her career, Eveline has supervised various MSc students and contributed to publications on topics like 3D printing of medicines and vaccine delivery systems.

Sejad Ayyoubi is pharmacist from background with several years of experience in developing personalized, 3D printed medicines. He is currently doing his PhD in the same topic at the Erasmus MC hospital pharmacy. The aim of his PhD is to translate this innovation from concept to clinical implementation. His work consists of the development, quality, costs, and clinical testing of 3D pharmaceuticals, with a focus on special drug release profiles.

 

Sneak preview speakers / panel members

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Maxime Annereau (Gustave Roussy)
Maxime Annereau has been a hospital pharmacist at Gustave Roussy since 2013, specializing in pediatric oncology and hematology. A former Paris hospital resident, he holds a Master’s degree in oncology (Université Paris-Saclay, 2010) and is currently pursuing a PhD (Université Paris-Saclay, 2022-2025). He contributed to the creation of a translational unit dedicated to innovative drug formulations and played a key role in developing a pediatric form of temozolomide, which was launched on the European market in collaboration with a start-up. As head of Gustave Roussy’s galenic and analytical translational unit, he focuses on unmet pharmaceutical needs and innovative projects. In 2024, he co-founded Pharma 3DPI to promote 3D printing of medicines.

 

Mariëlle Bouma (Dutch Health and Youth Care Inspectorate (IGJ))
Mariëlle Bouma is a pharmacist by training from the University of Groningen and worked for over twenty years in pharmaceutical and food industry. She worked in as well quality as manufacturing roles for several companies before she started as GMP Inspector for the Dutch Health and Youth Care Inspectorate (IGJ) in 2023. Her main focus is on industrial manufacturing of medicinal products.

 

Robert Flint (Erasmus MC)
Robert Flint is a hospital pharmacist and clinical pharmacologist in the Erasmus MC Sophia Children’s Hospital with a focus on the intensive care neonatology and obstetrics. Besides patient care, his research aims to determine optimal drug dosages for the most vulnerable premature born infants and during pregnancy. This has led to multiple descriptions of the pharmacokinetic profile of currently used drugs in (preterm) neonates, dose-finding exercised relating PK with PD, and a large ongoing randomised controlled drug trial. Furthermore, from his clinical pediatric perspective he collaborates to enable safe and acceptable drug formulations for all ages. As an editorial board member of the Dutch pediatric drug formulary, Robert has short connections to implement these findings in clinical practice.

 

Johan de Graaf (Dutch Pituitary Foundation)
Johan de Graaf is well-known in the field of patient advocacy, particularly for those with hypothalamic and pituitary conditions. Diagnosed with a tumor in the hypothalamic and pituitary region in 2007, Johan’s personal experience with the condition led him to become deeply involved in patient support and advocacy.
He has been the Chair of the Dutch Pituitary Foundation since 2015, where he has worked tirelessly to support patients and raise awareness about pituitary disorders. Johan also co-chairs the patient board of the European Society for Endocrinology and is involved in the European Reference Network on Rare Endocrine Conditions (Endo-ERN) as the ePAG co-chair for the Main Thematic Group on Hypothalamic and Pituitary Conditions.
In addition to his advocacy work, Johan has contributed to health technology assessment (HTA) bodies on the reimbursement of new medicines and is has been a national expert for the European Medicines Agency (EMA). His efforts in patient advocacy have been recognized with his election to the EURORDIS Board of Directors in 2024. Within the context of Endo-ERN Johan performed research on the unmet medical of social needs of patients living with a rare endocrine disorder. Johan’s dedication to improving the lives of those with pituitary conditions is evident through his extensive involvement in various organizations and his continuous efforts to advance research, education, and patient support.

 

Alvaro Goyanes (Fabrx, USC)
Alvaro is co-founder and CEO at FABRX, the first company focused on developing 3D printing technology for fabrication of personalised medicines and medical devices. He is also Lecturer at the Faculty of Pharmacy – University of Santiago de Compostela (Spain) and Honorary Lecturer at University College London – School of Pharmacy (UK). Alvaro is one of the first researchers to evaluate the opportunities of 3D printing using new 3D printing technologies to manufacture oral dosage forms and medical devices. He has been listed amongst the World’s Most Highly Influential Researchers for six years from 2019 by Web of Science and he is a recognized world expert in 3D printing of medicines. He is Director and cofounder of the Pharmaceutical 3D Printing Initiative, consortium dedicated to advancing the utilisation of 3D printing in the pharmaceutical field. He holds a PhD in Pharmaceutics from University of Santiago de Compostela (Spain) and he worked for 3 years as a Registered Pharmacist, thus has first-hand knowledge of the needs in terms of medicines in the community pharmacy.

 

Ricarda Leister (Meggle Pharma Excipients & Technology)
Ricarda is an accomplished leader with over 20 years in the pharmaceutical industry. As Head of Research & Development at MEGGLE Excipients, she leads a team driving innovation in excipients and technology, providing formulation support for pharmaceutical companies. She has worked with renowned companies like BASF, Boehringer Ingelheim, Merck, Procter & Gamble, and STADA. Ricarda holds an MBA and a degree in Pharmaceutical Engineering. Her expertise includes solid dosage forms, with a passion for advancing manufacturing science, technology, and digitalization to foster innovation and create customer value.

 

Ali Nasser Eddine (DiHeSys)

 

Nico van Meeteren (Erasmus MC, Executive Director Topsector Life Sciences and Health)
Van Meeteren earned his PhD as a Neuroscientist from the Rudolf Magnus Institute for Neurosciences of the Utrecht University in 1994. After 18 years of innovation and scientific validation of prevention, care and cure concepts and educational MSc-models in connection with the University Medical Centre Utrecht, he became Director of Innovation “Healthy for Live” at TNO in 2008. Van Meeteren was Professor at Maastricht University and held board memberships of amongst others the National Platform Sports and Physical Activity, Body@Work, and the Center for Care Technology Research. Since 2015, he has served as the Executive Director and Secretary General of the Top Sector Life Sciences & Health (Health~Holland). Furthermore, Van Meeteren is Professor of Perioperative Health at Erasmus Medical Center. Related to these appointments he holds several governance positions within the societal theme “Health and Care” of the the Dutch government’s Mission-driven Innovation Policy.

 

Margot Niewenweg-Camp (Dutch Health and Youth Care Inspectorate (IGJ))
Margot Nieuwenweg-Camp is a pharmacist by education, graduated from Utrecht University. Before joining the Dutch Health and Youth Care Inspectorate (IGJ) in 2020 she worked in several public pharmacies with compounding facilities in the Netherlands. At the IGJ she always worked in the field of medicinal products. The last two years as a GMP inspector with a special interest in drug manufacturing in (hospital) pharmacies including 3D printing.

 

Patrick van Oirschot (GGP Support)
Patrick van Oirschot is an experienced consultant in hospital pharmacy and a managing partner at GPP Support since 2013. He has a strong background in project management, strategic consulting, and new business development. Patrick has been involved in various leadership roles, from new business development for the pharma wholesaler to founding the Pharmacy Leadership Foundation. He is also the co-founder of the Asclepius Project, where he, along with pharmacists from over seven countries, is committed to raising awareness, developing, and transitioning to Closed Loop Medication Management.
He holds a master’s degree in econometrics and has published several white papers on pharmaceutical care, medication safety, supply chain, leadership development, return on investment and strategy development.
Patrick’s interest in personalised medicine with 3DP started in 2017. Since then, he has been involved in several 3DP initiatives, given presentations, and moderated podium discussions on how to elevate 3DP into clinical practice.

 

Niels Ouwerkerk (Doser)
Niels Ouwerkerk holds a PHD in Bio-Organic Synthesis from the Leiden University and has over 20 years of industrial experience in diverse industries, such as personal care, food specialties and pharmaceuticals.  His expertise covers areas in analytical development and validation, formulation development, quality assurance, and regulatory compliance.

 

Mattias Paulsson (Hospital Pharmacy Uppsala University)
Mattias Paulsson, PhD, is deputy chief pharmacist at Uppsala University Hospital, Sweden, with extensive experience in hospital pharmacy, formulation science, and 3D printing of pharmaceuticals. He has led extemporaneous compounding units, including radiopharmaceuticals and clinical trial preparations, and served as a GMP-qualified person. His research focuses on patient safety, parenteral nutrition, IV compatibility, and innovative drug delivery. He supervises undergraduate and PhD students, lectures on formulation science, and has published 28 scientific articles. Paulsson is dedicated to advancing pharmacy practice through both clinical and academic initiatives.

 

Holger Reinhoff (DiHeSys)

 

Niklas Sandler (CurifyLabs)
Niklas Sandler, PhD (Pharm,), Founder and Chief Technology Officer (CTO) at CurifyLabs. He has extensive experience in academia and industry, specialising in pharmaceutical product development and material science. His research in pharmaceutical technology has been published in over 100 papers in major international journals. Sandler’s academic work as professor at Åbo Akademi University (2009-2019) focused on novel pharmaceutical manufacturing technologies, process analytics, formulations for additive manufacturing (3D printing) and material characterisation.Between 2019-2022 he was Chief Technology Officer at Nanoform Finland Ltd. CurifyLabs was founded in 2021 and is CurifyLabs is offering a unique approach to compounding medicines in pharmacies and hospital pharmacies through high-quality 3D printing of personalized medicines on site in pharmacies.

 

Kirsten Schimmel (Leiden University Medical Center)
Kirsten Schimmel, PharmD, PhD is an associate professor in drug manufacturing. She is head of the GMP production facility of clinical pharmacy at the academic hospital of Leiden. The facility has GMP licenses for conventional medicines, ATMPs, small molecules and radiopharmaceuticals. She is also educational director of the Master of Pharmacy at the University of Leiden.
Since 2018 she is involved in research in 3D pharma printing, with the ultimate goal of bringing this innovative production technique to the point of care.

 

Laurens Schulpen (Service Apotheek Woerden)
Laurens Schulpen has been a community pharmacist in Woerden since 2001. Together with four colleague pharmacists, they provide pharmaceutical care for a large part of Woerden. There are always one or two AIOS working in his pharmacy who are being trained to become community pharmacists. Besides education, Laurens has a broad interest in pharmaceutical care. Compounding and “baxtering” are important aspects of his pharmacy. Recently, the pharmacy acquired a 3D printer from Doser. Laurens is also active in administrative roles. He is the chairman of the Central College of Pharmacy Specialties, chairman of the Landelijke Eerstelijns Farmacie (LEF), a member of the Franchise Council of Service Apotheek, and a member of the NedAIS (representatives of all user associations of AIS in the Netherlands). Laurens is convinced that 3D printing of tablets will in the near future play an important role in personalized patient treatment.

 

Tilmann Spitz (GoatAM)
Tilmann Spitz is CEO and co-founder of goatAM. Before joining goatAM as CEO, Mr Spitz worked in research at the Technical University of Cologne, where he also completed his master’s degree in mechanical engineering with a focus on automation technology. As part of his research activities, Mr Spitz dealt with smart sensor technology, highly dynamic measuring systems and the implementation of AI algorithms in machine systems for quality control, among other things. The main focus of his work was additive manufacturing, where he created highly specialised machine systems for special applications and materials. For example, he developed 3D printing systems for construction foams, multi-material applications and pharmaceutical applications. In 2023, he founded goatAM with a 3D printing system for the decentralised production of individual pharmaceutical dosage forms.

 

Karel Stolper ( CbusineZ)
Karel Stolper is an expert in healthcare innovation and financing, with a background in health economics, management, and policy. He is the CEO of CbusineZ, the innovation and investment arm of CZ, where he oversees a diverse portfolio of healthcare ventures. His work focuses on fostering and scaling innovations that improve accessibility, efficiency, and quality in healthcare.

With a PhD in Health Economics from Erasmus University and previous leadership roles in health insurance and healthcare strategy, Karel has gained understanding of regulated market dynamics and healthcare transformation. He is also a guest researcher at the Erasmus School of Health Policy and Management and serves on various boards, including those advancing self-care solutions and homecare innovation.

 

Jesse Swen (Leiden University Medical Center)
Jesse Swen PharmD, PhD is a full professor of clinical pharmacy, in particular translational pharmacogenetics. He works as a clinical pharmacist-clinical pharmacologist at the Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center where he is the chair of the laboratory of the hospital pharmacy.
The long-term central goal of his career is to improve the outcomes of drug treatment by gaining a better understanding of the genetic mechanisms that result in inter-individual variability in drug response.

René Thürmer (Federal Institute for Drugs and Medical Devices, Bonn)
Dr. René Thürmer received his diploma in chemistry and his Ph.D. in biochemistry from the University of Tübingen. He joined the BfArM (Federal Institute for Drugs and Medical Devices, Bonn, Germany) in 2000. He currently serves as a CMC reviewer and is Deputy Head of the Unit Pharmaceutical Biotechnology, Genetic and Reproductive Toxicology.
His experience is in the field of formulation, manufacture and control of medicinal products, in particular in the field of oligonucleotides, peptides, proteins, liposomes, sustained release polymer drug products, depot formulations, polymer-conjugated drug products, natural and synthetic surfactants, nanomedicine and others.
He is a member of the EMA Quality Innovation Group (QIG) established in 2022.